Market Place
Sourcing Support
AcelRx becomes Talphera, adopting new name to reflect pain pivot
10 Jan 2024 //
FIERCE PHARMA
AcelRx Announces Rebranding With Name Change to Talphera, Inc.
09 Jan 2024 //
PR NEWSWIRE
AcelRx Announces Publication of Study Evaluating Anticoagulation Practices
12 Dec 2023 //
PR NEWSWIRE
AcelRx Reports Third Quarter 2023 Financial Results
08 Nov 2023 //
PR NEWSWIRE
AcelRx to Host KOL Panel Discussion on Current Anticoagulant Use in Dialysis
07 Nov 2023 //
PR NEWSWIRE
AcelRx to Host Third Quarter 2023 Financial Results Call
26 Oct 2023 //
PR NEWSWIRE
AcelRx Receives IDE Approval for Niyad & Advances to Single Registration Study
03 Oct 2023 //
PR NEWSWIRE
AcelRx to Participate in the H.C. Wainwright Annual Investment Conference
06 Sep 2023 //
PR NEWSWIRE
AcelRx Reports Second Quarter 2023 Financial Results
10 Aug 2023 //
PR NEWSWIRE
AcelRx to Host Second Quarter 2023 Financial Results Call
27 Jul 2023 //
PR NEWSWIRE
AcelRx Pharma Announces Closing of Previously Announced Private Placement
21 Jul 2023 //
PR NEWSWIRE
AcelRx Pharmaceuticals Announces $10 Million Private Placement of Securities
18 Jul 2023 //
PR NEWSWIRE
AcelRx to Host 1Q 2023 FYR Call and Webcast on May 10, 2023
27 Apr 2023 //
PR NEWSWIRE
AcelRx Announces Closing of Divestment of DSUVIA® to Alora Pharmaceuticals
05 Apr 2023 //
PR NEWSWIRE
AcelRx Reports Full Year and 4Q Financial Results 2022 Financial Results
30 Mar 2023 //
PR NEWSWIRE
AcelRx to Host Full Year and Fourth Quarter 2022 Financial Results Call
21 Mar 2023 //
PR NEWSWIRE
AcelRx Pharmaceuticals Announces Divestment of DSUVIA® to Alora Pharmaceuticals
14 Mar 2023 //
PR NEWSWIRE
AcelRx Pharmaceuticals Announces Peer-Reviewed Publication On the Use of DSUVIA
01 Mar 2023 //
PR NEWSWIRE
AcelRx Announces Presentation of Plastic Surgery Procedures with DSUVIA
31 Oct 2022 //
PRNEWSWIRE
AcelRx Announces the European Launch of DZUVEO by its Partner, Aguettant
27 Oct 2022 //
PRNEWSWIRE
AcelRx to Present Trial Result Comparing AcelRx`s SST Versus Intravenous Opioids
26 Oct 2022 //
PRNEWSWIRE
AcelRx to Participate in the H.C. Wainwright Annual Investment Conference
06 Sep 2022 //
PRNEWSWIRE
AcelRx Pharmaceuticals Reports Q2 2022 Rusult and Provides Corporate Update
11 Aug 2022 //
PRNEWSWIRE
AcelRx Pharma Announces Abstract Acceptance at the ANESTHESIOLOGY 2022
10 Aug 2022 //
PR NEWSWIRE
AcelRx to Host Second Quarter 2022 Financial Results Call and Webcast
28 Jul 2022 //
PRNEWSWIRE
AcelRx Pharma to Participate in the H.C. Wainwright Global Investment Conference
20 May 2022 //
PRNEWSWIRE
AcelRx Pharma Provides Update on Reduced FDA REMS Requirements Related to DSUVIA
19 May 2022 //
PRNEWSWIRE
AcelRx Pharmaceuticals Reports First Quarter 2022 Financial Results
16 May 2022 //
PRNEWSWIRE
AcelRx to Publish Results from Investigator-Initiated Trial on SST
10 May 2022 //
PRNEWSWIRE
AcelRx to Host First Quarter 2022 Financial Results Call
09 May 2022 //
PRNEWSWIRE
AcelRx Hosting Key Opinion Leader Webinar on Niyadâ„¢ Nafamostat Program
27 Apr 2022 //
GLOBENEWSWIRE
Minimal Side Effects and Short Recovery Time Reported for DSUVIA®
25 Apr 2022 //
PRNEWSWIRE
AcelRx Pharmaceuticals Announces Upcoming Podium Presentation on Use of DSUVIA®
21 Apr 2022 //
PRNEWSWIRE
AcelRx Pharma to Publish Data Finding Potential Benefits of Nafamostat
29 Mar 2022 //
PRNEWSWIRE
AcelRx Pharmaceuticals Reports Q4 and Full Year 2021 Financial Results
10 Mar 2022 //
PRNEWSWIRE
AcelRx to Host Fourth Quarter and Full Year 2021 Financial Results
03 Mar 2022 //
PRNEWSWIRE
AcelRx Pharma Publishes Article Showing Utility of Sufentanil Sublingual Tablet
27 Jan 2022 //
PRNEWSWIRE
AcelRx to publish Opioid-Sparing Surgery Showing Potential of Sufentanil
12 Jan 2022 //
PRNEWSWIRE
AcelRx Pharmaceuticals Announces the Appointment of Jill Broadfoot
23 Nov 2021 //
PRNEWSWIRE
AcelRx to Acquire Lowell Therapeutics and Reports Q3 2021 Financial Results
15 Nov 2021 //
PRNEWSWIRE
AcelRx Announces $14M Registered Direct Common Stock and Warrant Offering
15 Nov 2021 //
PRNEWSWIRE
AcelRx Pharmaceuticals to Participate in Two September Investor Conferences
10 Sep 2021 //
PRNEWSWIRE
Presentation on the Effect of the Administration of Sufentanil Sublingual Tablet
26 Aug 2021 //
PRNEWSWIRE
The Law of Frank R. Cruz the Filing Securities Class Action Behalf AcelRx
21 Jul 2021 //
PRNEWSWIRE
AcelRx Enters into Licensing Agreement for DZUVEO® in Europe
14 Jul 2021 //
PRNEWSWIRE
AcelRx Enters into Licensing Agreement for DZUVEO® in Europe
14 Jul 2021 //
PRNEWSWIRE
Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline
23 Jun 2021 //
PRNEWSWIRE
AcelRx Announces Agreement with FDA for Warning Letter Received for DSUVIA
17 Jun 2021 //
PRNEWSWIRE
AcelRx initiates study of DSUVIA in Emergency Dept for Patients with Sickle Cell
20 May 2021 //
PRNEWSWIRE
AcelRx Announces an Investigator-Initiated Study of DSUVIA® for Use in Same-Day
06 May 2021 //
PRNEWSWIRE
AcelRx Announces an Investigator-Initiated Study of DSUVIA®
08 Apr 2021 //
PRNEWSWIRE
AcelRx Announces an Investigator-Initiated Study of DSUVIA®
08 Apr 2021 //
PRNEWSWIRE
AcelRx Announces Clinical Data Reporting High Ratings for Healthcare
25 Mar 2021 //
PRNEWSWIRE
AcelRx Announces Presentation and Fireside Chat at the Benzinga Biotech
22 Mar 2021 //
PRNEWSWIRE
AcelRx to Host Fourth Quarter & Full Year 2020 Financial Results Call & Webcast
08 Mar 2021 //
PRNEWSWIRE
FDA rebukes AcelRx for promo for potent opioid drug Dsuvia
19 Feb 2021 //
FIERCE PHARMA
AcelRx Announces an Investigator-Initiated Study of DSUVIA®
17 Feb 2021 //
PRNEWSWIRE
AcelRx Announces Underwritten Public Offering of Common Stock
19 Jan 2021 //
PRNEWSWIRE
AcelRx Announces an Investigator-Initiated Study of DSUVIA® in Cardiac Surgery
19 Jan 2021 //
PRNEWSWIRE
